A comparison of Cynata’s innovative Cymerus™ platform to conventional MSCs has been highlighted in a study published in npj Regenerative Medicine, a prestigious peer-reviewed journal by Nature Portfolio.

The study, led by Monash University researchers found significant advantages of Cynata’s iPSC-derived MSCs in consistency, regenerative potential, and immunomodulatory effects and key differences between MSCs from various sources, with Cynata’s platform showcasing unique benefits for therapeutic applications.

Read the news coverage here: https://tinyurl.com/y8fpntk4